帕洛诺司琼防治乳腺癌化疗相关性恶心呕吐的临床对照研究

目的 观察帕洛诺司琼防治乳腺癌化疗相关性恶心呕吐的疗效及安全性.方法 选择2010年1月-2013年6月沈阳军区总医院收治的乳腺癌77例,其中帕洛诺司琼组（A组）38例和托烷司琼组（B组）39例.两组患者均采用含表柔比星方案化疗,分别观察两组化疗后0~5 d内出现恶心、呕吐及食欲不振等消化道反应和便秘、头晕等不良反应.结果化疗后0~24 h两组恶心、呕吐及食欲不振控制率差异均无统计学意义（P＞0.05）,化疗后2~5 d A组对恶心、呕吐控制率明显优于B组（P＜0.05）,食欲不振控制率无差异（P＞0.05）.两组不良反应较轻,无明显差异（P＞0.05）.结论 在乳腺癌化疗中,帕洛诺司琼防治表柔比星引起迟发性恶心呕吐疗效显著,安全性高.

A Clinical Study of Palonosetron in Prevention of Chemotherapy-related Nausea and Vomiting in Patients with Breast Cancer

Objective To observe the curative effect and safety of Palonosetron in prevention of chemotherapy- related nausea and vomiting in patients with breast cancer. Methods A total of 77 inpatients with breast cancer during January 2010 and June 2013 were randomly divided into Palonosetron group （group A, n = 38） and Tropisetron group （group B, n = 39）. All the patients underwent Epirubicin-containing chemotherapy. The episodes of loss of appetite, nausea and vomiting, and adverse effects such as constipation and dizziness in the two groups within 0-5 d after the chem- otherapy were observed. Results The control rates for loss of appetite, nausea and vomiting in the two groups within 0 - 24 h after chemotherapy showed no statistical differences （ P 〉 0.05 ）. The control rates for nausea and vomiting in group A within 2 - 5 d after chemotherapy were significantly better than those in group B （P 〈 0. 05）, but the difference in control rate for loss of appetite was not statistically significant （P 〉 0.05）. No serious adverse effect was observed in the two groups （P 〉 O. 05）. Conclusion Palonosetron has significant efficacy and high safety in prevention of chemo- therapy-related tardive nausea and vomiting in Epirubicin-containing chemotherapy for breast cancer.